DeepMind Spinout Fuels AI Drug Design with Mega-Round
Isomorphic Labs, a cutting-edge company leveraging artificial intelligence for drug discovery and development, has secured a staggering $2.1 billion in Series B funding. The significant capital injection, announced on May 12, 2026, is poised to propel the London-based startup's mission to "solve all disease" through advanced AI capabilities. The funding round was co-led by Thrive Capital, with substantial participation from existing backers Alphabet and GV, alongside new strategic investors including MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. This massive investment underscores a surging global confidence in AI-driven healthcare innovation and its potential to drastically shorten the drug development lifecycle.
Accelerating Breakthroughs in Medicine
Founded in 2021 by AI luminary Sir Demis Hassabis, who also co-founded Google's DeepMind, Isomorphic Labs is at the forefront of reimagining pharmaceutical research. The company has developed a proprietary AI drug design engine, referred to as IsoDDE, which integrates foundational AI models capable of operating across diverse therapeutic areas and drug modalities. This advanced engine is designed to work with unprecedented precision and speed, aiming to overcome some of the most complex biological and medical challenges. The newly acquired funds will be instrumental in scaling this engine, further developing its capabilities, and accelerating the progression of its therapeutic programs towards clinical trials. Furthermore, the investment will support the company's aggressive hiring targets, bringing in world-class talent in AI, engineering, and drug design across its global sites.
UK Government's Sovereign AI Fund Signals Strategic Investment
The participation of the UK Sovereign AI Fund in this funding round highlights a strategic governmental push to bolster the nation's artificial intelligence sector. Launched just last month, the Sovereign AI Fund is designed to invest in promising early-stage AI companies, helping them to grow and scale within the UK. Science and Technology Secretary Liz Kendall emphasized the transformative potential of Isomorphic Labs' work, stating, "Isomorphic Labs' ground-breaking work has the potential to reshape completely how medicines are discovered – cutting years off development and giving real hope to people living with devastating diseases." This investment aligns with the UK's broader ambition to become a global leader in AI, fostering domestic innovation and preventing high-growth companies from relocating overseas.
A New Era of AI-Driven Drug Design
Sir Demis Hassabis expressed his enthusiasm for the funding, calling it "a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development." He added, "Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential." The company's first-principles approach, which treats drug discovery as an integrated scientific and engineering discipline powered by proprietary AI and data, positions it to define the future of the field. With this substantial funding, Isomorphic Labs is set to make significant strides in delivering scientific breakthroughs that were previously considered impossible, ultimately aiming to address the global burden of disease.
Looking Ahead
Isomorphic Labs' monumental funding round signals a pivotal moment for AI in healthcare. As the company scales its operations and advances its drug candidate pipeline, the industry will be watching closely to see how its AI-driven breakthroughs translate into tangible treatments for some of the world's most pressing health challenges. The continued support from major tech investors and government initiatives underscores the immense potential of AI to revolutionize medicine.